HC Wainwright & Co. Initiates Coverage On Cardiol Therapeutics with Buy Rating, Announces Price Target of $9
Cardiol Therapeutics Inc Ordinary Shares - Class A -3.30% Post
Cardiol Therapeutics Inc Ordinary Shares - Class A CRDL | 2.05 2.05 | -3.30% 0.00% Post |
HC Wainwright & Co. analyst Vernon Bernardino initiates coverage on Cardiol Therapeutics (NASDAQ:
CRDL) with a Buy rating and announces Price Target of $9.